Physician profile
Christopher Haas
NPI 1821520115
$48,787.23
in general payments reported to CMS, 2019-2025
25 companies · $29K in 2025
The $29K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.23 · 2020: $100 · 2021: $697 · 2022: $2,242 · 2023: $3,519 · 2024: $14K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $8,873 · Food and Beverage: $3,425 · Travel and Lodging: $1,813 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,600.00 |
| Consulting Fee | $8,872.50 |
| Food and Beverage | $3,425.42 |
| Travel and Lodging | $1,813.37 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34,184.69 | 2020-2025 | |
| Janssen Biotech, INC. | $7,331.60 | 2022-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $3,067.37 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $673.25 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $486.21 | 2022-2025 | |
| Lilly USA, LLC | $429.88 | 2022-2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $347.70 | 2021-2025 | Nemluvio, Dysport |
| Ucb, INC. | $342.64 | 2022-2024 | Bimzelx |
| Amgen INC. | $306.26 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $234.70 | 2022-2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $229.69 | 2022-2024 | Dupixent |
| Leo Pharma INC. | $214.65 | 2022-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $186.22 | 2022 | |
| Pfizer INC. | $159.03 | 2025 | |
| Botanix Sb INC | $141.69 | 2025 | Sofdra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $112.17 | 2022-2024 | Poteligeo |
| Allergan, INC. | $66.35 | 2022 | |
| Melinta Therapeutics, LLC | $62.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.02 | 2023-2025 | Spevigo |
| Mallinckrodt Hospital Products INC. | $36.96 | 2024 | Acthar |
| Sanofi-Aventis U.S. LLC | $35.90 | 2020-2021 | |
| Triad Life Sciences INC. | $31.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.92 | 2025 | Cuvitru |
| Arcutis Biotherapeutics, INC. | $16.68 | 2023 | |
| Celgene Corporation | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.